| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8827900 | European Urology Focus | 2017 | 7 Pages |
Abstract
We performed a systematic review to assess outcomes and toxicity of stereotactic body radiotherapy (SBRT) for patients affected by oligorecurrent prostate cancer limited to lymph nodes. We concluded that SBRT is a promising therapy in this setting, but it needs to be validated in randomized controlled trials.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Elisabetta Ponti, Andrea Lancia, Piet Ost, Fabio Trippa, Luca Triggiani, Beatrice Detti, Gianluca Ingrosso,